Lilly's New Pill: A Weight Loss Game-Changer?

Eli Lilly's orforglipron, an experimental GLP-1 pill, showed promise in weight reduction, helping patients lose 12.4% of body weight in a trial, less than compared to Novo Nordisk's Wegovy. Despite market anticipation for better results, Lilly remains optimistic about FDA approval and addressing early demand through stockpiling.

Eli Lilly's experimental GLP-1 pill, orforglipron, demonstrated significant weight loss results, according to a recent late-stage trial. Patients lost an average of 12.4% body weight over 72 weeks. However, this was below the 14.9% weight reduction achieved by Novo Nordisk's injectable Wegovy, leading to nearly an 11% drop in Lilly's premarket shares.

Despite not matching Wegovy's results, Lilly is optimistic about orforglipron's potential. Unlike injectable treatments, orforglipron is a small molecule pill that is easier to produce and administer. It offers a daily intake option that can be used for early intervention and sustained disease management. Lilly plans to seek regulatory approval for the pill by year-end.

In a 3,000-person study, orforglipron effectively reduced weight in non-diabetic, overweight adults while also lowering heart disease markers. The study noted some mild-to-moderate side effects, with nausea and vomiting being the most common. The full results are anticipated to be presented at an upcoming European diabetes meeting, highlighting the drug's long-term potential in the weight-loss sector.